Jove
Visualize
Contact Us

Related Experiment Videos

Chemotherapy-associated hematopoietic toxicity.

John G Kuhn1

  • 1College of Pharmacy, Departments of Pharmacology and Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-6220, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|August 9, 2002
PubMed
Summary

Managing chemotherapy side effects like low platelets (thrombocytopenia), low white blood cells (neutropenia), and anemia is crucial. Early detection and management of these hematopoietic toxicities improve patient outcomes and quality of life during cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).

Breast cancer research : BCR·2019
Same author

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019
Same author

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2018
Same author

A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier.

Pharmaceutics·2018
Same author

Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts.

Molecular pharmaceutics·2018
Same author

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

The Lancet. Oncology·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Antineoplastic therapies can cause significant hematopoietic toxicity, including thrombocytopenia, neutropenia, and anemia.
  • These toxicities pose serious risks, such as hemorrhage from thrombocytopenia and infection from neutropenia.
  • Anemia, a common side effect, significantly impacts patient quality of life due to fatigue.

Purpose of the Study:

  • To discuss strategies for managing antineoplastic therapy-associated hematopoietic toxicity.
  • To highlight the risks and management approaches for thrombocytopenia, neutropenia, and anemia.
  • To explore current and emerging treatments for chemotherapy-induced anemia.

Main Methods:

  • Review of established clinical practices for managing chemotherapy-induced cytopenias.

Related Experiment Videos

  • Discussion of risk factors and clinical implications of thrombocytopenia, neutropenia, and anemia.
  • Evaluation of treatment options, including transfusions and epoetin alfa for anemia.

    • Main Results:

    • Thrombocytopenia (<20,000 platelets/µL) increases hemorrhage risk.
    • Neutropenia severity and duration correlate with infection risk; routine cytokine use may not be cost-effective.
    • Fatigue is a prevalent symptom of anemia, often undertreated; epoetin alfa offers a promising alternative to transfusions.

    Conclusions:

    • Chemotherapy-induced hematopoietic toxicity is a complex, multifactorial challenge in oncology.
    • Effective management strategies are essential for patient safety and treatment adherence.
    • Emerging therapies like epoetin alfa are improving anemia management and enabling more aggressive cancer treatment.